BACKGROUND: The goal of this study was to determine whether the production of posttransplant antibodies directed against donor HLA mismatches (donor specific antibody; DSA) is associated with renal allograft rejection and early graft dysfunction. METHODS: Forty-nine adult renal allograft recipients with increased risk of rejection were enrolled during the period of October 2001 through May 2003 and were prospectively monitored for the development of anti-HLA antibodies. RESULTS: Of 49 patients, eight (16.3 %) patients were diagnosed with acute humoral rejection (AHR) and 11/49 (22.4%) patients were diagnosed with acute cellular rejection (ACR). A strong association between pretransplant HLA sensitization and AHR was found (P=0.005). Of the eight patients diagnosed with AHR, the majority developed DSA before or concomitant with episodes of rejection (P<0.001). Only 3 of 41 patients (7.3%) without AHR developed DSA. The pathogenic role of alloantibodies was further substantiated by analyzing their association with graft function as measured by serum creatinine levels. The average serum creatinine after the third month posttransplantation in DSA producers was 2.24+/-1.01 mg/dL, while in non-DSA patients the average serum creatinine was 1.41+/-0.37 mg/dL (P<0.01). CONCLUSION: This study reveals a strong association between the production of DSA, AHR, and early graft dysfunction. Our findings indicate that prospective monitoring for anti-HLA antibodies following transplantation is a useful test for the diagnosis and classification of AHR for identifying patients at risk of early graft dysfunction.
BACKGROUND: The goal of this study was to determine whether the production of posttransplant antibodies directed against donor HLA mismatches (donor specific antibody; DSA) is associated with renal allograft rejection and early graft dysfunction. METHODS: Forty-nine adult renal allograft recipients with increased risk of rejection were enrolled during the period of October 2001 through May 2003 and were prospectively monitored for the development of anti-HLA antibodies. RESULTS: Of 49 patients, eight (16.3 %) patients were diagnosed with acute humoral rejection (AHR) and 11/49 (22.4%) patients were diagnosed with acute cellular rejection (ACR). A strong association between pretransplant HLA sensitization and AHR was found (P=0.005). Of the eight patients diagnosed with AHR, the majority developed DSA before or concomitant with episodes of rejection (P<0.001). Only 3 of 41 patients (7.3%) without AHR developed DSA. The pathogenic role of alloantibodies was further substantiated by analyzing their association with graft function as measured by serum creatinine levels. The average serum creatinine after the third month posttransplantation in DSA producers was 2.24+/-1.01 mg/dL, while in non-DSA patients the average serum creatinine was 1.41+/-0.37 mg/dL (P<0.01). CONCLUSION: This study reveals a strong association between the production of DSA, AHR, and early graft dysfunction. Our findings indicate that prospective monitoring for anti-HLA antibodies following transplantation is a useful test for the diagnosis and classification of AHR for identifying patients at risk of early graft dysfunction.
Authors: Abanti Chaudhuri; Mikki Ozawa; Matthew J Everly; Robert Ettenger; Vikas Dharnidharka; Mark Benfield; Robert Mathias; Anthony Portale; Ruth McDonald; William Harmon; David Kershaw; V Matti Vehaskari; Elaine Kamil; H Jorge Baluarte; Bradley Warady; Li Li; Tara K Sigdel; Szu-chuan Hsieh; Hong Dai; Maarten Naesens; Janie Waskerwitz; Oscar Salvatierra; Paul I Terasaki; Minnie M Sarwal Journal: J Am Soc Nephrol Date: 2013-02-28 Impact factor: 10.121
Authors: Josefina Alberu; Maria Inés Vargas-Rojas; Luis E Morales-Buenrostro; Jose C Crispin; Roxana Rodríguez-Romo; Norma O Uribe-Uribe; Gabriel Carrasco; Diana Gómez-Martín; Jorge Alcocer-Varela Journal: J Transplant Date: 2012-08-23
Authors: Jason M Zimmerer; Matthew W Basinger; Bryce A Ringwald; Mahmoud Abdel-Rasoul; Ronald P Pelletier; Amer Rajab; Ashraf El-Hinnawi; Hemant Parekh; Kenneth Washburn; Ginny L Bumgardner Journal: Transplantation Date: 2020-11 Impact factor: 5.385